Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients

Anticancer Research

Volumn 19, Issue 4 C, 1999, Pages 3511-3515

  Lauro, Salvatore ^a,b   Trasatti, Luciana ^a   Bordin, Francesca ^a   Lanzetta, Gaetano ^a   Bria, Emilio ^a   Gelibter, Alain ^a   Gabriella Reale, M ^a   Vecchione, Aldo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

Breast cancer; CA 15 3; CA 27 29; Serum markers

Indexed keywords

CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; FLUOROURACIL; FORMESTANE; GOSERELIN; LETROZOLE; METHOTREXATE; NAVELBINE; TAMOXIFEN; TAXANE DERIVATIVE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; SEROLOGY;

ADULT; AGED; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BONE NEOPLASMS; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; RECURRENCE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0033453299     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Gold P, Freedman SO: Demonstration of tumor-specific antigen in human colonic carcinoma by immunological tolerance and adsorption techniques. J Exp Med 131: 439-462, 1965.
2. Dolen AV: New markers for breast carcinoma-associated antigen in comparision with CA 15-3. Anticancer Res 16: 2339-2344, 1996.
3. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J et al: Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 265: 15286-15293, 1990.
4. Seregni E, Betti C, Massoran S, Martinetti A, Ferrani L, Merini Molteni S and Bombardieri E: Mucinous markers in breast cancer. Tumori 83: 550-551, 1997.
5. Stahli B, Takaes V, Miggiano et al: Monoclonal antibodies against antigens of breast cancer cells. Experientia 41: 1377-81, 1985.
6. Tobias R, Rothwell C, Wagner J, Green A, Lin YS: Development and evluation of a radioimmunoassay for the detection of a monoclonal antibody defined breast tumor associated 115D8/DF3. Clin Chem 31: 986, 1985.
7. Reddish MA, Helbrecht N, Almeida AF et al: Epitope mapping of MAB B27-29 within the peptide core of the malignant breast carcinoma-associated mucin antigen coded for by the human MUC I gene. J Tumor Marker Oncol 7: 19-27, 1992.
8. Chan DW, Beveridge RA, Muss M, Fritsche MA, Hortobagyi G, Therian R, Kiang D, Kennedy B-J and Evelegh M: Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 15(6): 2322-2328, 1997.
9. Adopted in May 17 1996 by the American Society of Clinical Oncology, Clinical practice guidelines for the use of tumor markers in Breast and Colorectal Cancer, J Clin Oncol 14(10): 2843-2877, 1996.
10. Safi F, Kohler I, Rottinger E, Beger HG: The value of the tumor marker CA 15-3 in diagnosing and monitoring Breast Cancer. A comparative Study with Carcynoembrionic Antigen. Cancer 68: 574-582, 1991..
11. Al-Jarallah MA, Behebehani AE, El-Nass SA, Temim L, Ebraheem AK, Ali MAA, Szymendera JJ: Serum CA 15-3 and CEA patterns in post-surgical follow-up and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur J Surg Oncol 19: 74-79, 1993.
12. Frenette PS, Thirlwell MP, Thomson DMP, Joseph L, Shuster J: The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryogenic antigen and CA 19-9 in breast and gastrointestinal malignancies. Tumor Biol 15: 247-254, 1994.
13. Correale M, Abbate J, Gargano A, Catino A, Dragone CD, Musci MD, Serio G, Paradiso A, De Luna A: Analytical and clinical evaluation of a new tumor marker in breast cancer: CA 27-29. Int J Biol Markers 7: 43-46, 1992.
14. Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno and Dogliotti G: Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 30 A(14): 2082-2084, 1994.
15. Eskelinen M, Hippelainen M, Kettunen J, Salmela E, Penttila L and Alhove E: Clinical value of serum tumor markers TPA, TPS, TAG 12, CA 15-3, MCA in breast cancer diagnosis: results from a prospective study. Anticancer Res 14: 699-704, 1994.
16. Miserez AR, Ilknur G, Muller-Brand J et al: Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparision with CA 15-3. Eur J Cancer 27: 126-131, 1997.
17. Mannier A, Ramardi A, Cambon R, Febre C, Namer M: Comparison of CEA, CA 153 and MCA in 473 breast cancer. J Tumor Marker Oncol 6: 42, 1991.
18. Gerarthy JG, Covenly EC, Sherry F, O'Hiigins NJ, and Duffy MJ: CA 15-3 in patients with locoregional and metastatic breast carcinoma. Cancer 70(12), 1994.
19. Vizcarra E, Leuch A, Cibrian R, Jinque F, Garcia-Conde J: CA 15-3, CEA, and TPA tumor markers in the early diagnosis of breast cancer relapse. Oncology 51: 491-496, 1994.
20. Aydiner A, Topuz E, Disei R, Yoseveri U, Dincer M, Dincol K and Bilgy N: Serum tumor markers for detection of bone metastasis in breast cancer patients. Acta Oncologica 33(2): 181-186, 1994.
21. Colomer R, Ruibal A, Salvador L: Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64: 1674-1681, 1989.
22. Depaterna R, Arzaiz P, Estenoz J, Ortuno B, Lanzos E: Study of serum tumor markers CEA, CA15-3 and CA 27-29 as diagnostic parameters in patients with breast carcinoma. J Biol Markers 10(1): 24-29, 1995.
23. Martoni A, Zamagni C, Bellanova B, Zanichelli L, Vecchi F, Caocciani N, Strocchi E and Pannuti F: CEA, MCA, CA 15-3, and CA S49 and their combinations in expressing and monitoring metastatic breast cancer o prospective comparahve study. Eur J Cancer 31A(10): 1615-1621, 199?.
24. Bombardieri E, Pizzichetta M, Veronesi P, Seregni E, Bagni A, Maffioli L, Soccani G et al: CA 15-3 determination in pattents with breast cancer: clinical utility for detection of distant metastases. Eur J Cancer 29 A(1): 144-146, 1993.
25. Molina R, Zanon G, Fililla et al: Use or serial carcinoembryogenic antigen and CA 15-3 assay in detecting relapses in breast cancer patients. Breast Cancer Res Treat 36: 41-48, 1995.
26. Repetto L, Onetto M, Gandin G, Costanzi B, Giudici S, Vitello E, Merlini L et al: Serum CEA, CA 15-3 and MCA in breast cancer patients: a clinical evaluation. Cancer Detection and Prevention 17(3): 411-415, 1993.
27. Kiang DT, Greenberg JL, Kennedy BJ: Tumor marker kinetics in the monitoring of breast cancer. Cancer 65: 193-199, 1990.
28. Tondini C, Hayes DF, Gelman R, Henderson JC, Kyte DW: Comparison of CA 15-3 and Carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 48: 4107-4112, 1988.
29. Robertson JFR, Pearson D Pnce MR et al. Assessment of four monoclonal antibodies as serum markers in breast cancer. Eur J Cancer 26: 1127-1132, 1990.
30. Laurence V, Forbes MA, Cooper EH: Use of mucin-like cancer associated antigen (MCA) in the management of breast cancer. Br J Cancer 63: 1000-1004, 1991.
31. Kiang DT, Gay J, Kennedy BJ: Circulating tumor marker CA 27-29 in monitoring clinical course of advanced breast cancer. Proc: Ann Meet Am Soc Clin Oncol 13: A267, 1994.
32. Adopted on November 7 1997 by the American Cancer Society,of Clinical Oncology, 1997 Update of recommendations for the use of tumor markers in Breast and Colorectal cancer. J Clin Oncol 16: 793-795, 1998.